skip to the content

Clinical Trials

Non-Small Cell Lung Cancer Study

Protocol ID

07.06.124

Protocol Description

This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have lung cancer recur (come back). 

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of lung cancer.  We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on patients and their lung cancer to see which is better at preventing the cancer from coming back. 

Eligibility Criteria

Patients with non-small cell lung cancer, that has been removed by a surgeon

Primary Investigator(s)

  • Rajasree Roy, MD

Contact Information

Dale Janson, RPA-C
(718) 470-4408
djanson@lij.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top